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Few data measure the problems critically ill patients have with medications after hospital discharge, 
which medications are involved, and how severe the consequences are (1-3). We sought to assess 
the prevalence and severity of medication related problems in intensive care unit (ICU) survivors and 
explore pain management strategies. We did so among patients attending a 5-site post-ICU 
programme in Scotland between September 2016 and June 2018. 
Methods 
Ethical approval was granted by The North West (Liverpool Central) Research Ethics Committee, REC 
Reference Number: 17/NM/0199.  All patients provided written consent.   
Intensive Care Syndrome: Promoting Independence and Return to Employment (InS:PIRE) is a 5-week 
rehabilitation programme for ICU survivors. Previous research has described this programme (4-
6).   Participants were invited between four- and twelve-weeks after hospital discharge. Patients were 
eligible if they received level three care or more than seven days of level two care. UK Level three 
patients require multiple organ support or invasive respiratory support alone. Level two patients are 
patients requiring single organ support or post-operative care (7).  Patients who were otherwise 
deemed high risk were invited (for example, one patient who received non-invasive ventilation for a 
prolonged duration was invited), as were patients who self-referred.   
 
A pharmacist provided a standardised review for all patients, this included: medicines reconciliation; 
assessment of medication appropriateness; identification of problems; assessing adherence; and 
providing education. Prescribed medications were documented at four time points: pre-ICU admission; 
ICU discharge; at hospital discharge and at InS:PIRE (at the start of the programme). Data were 
gathered from primary care, in-hospital notes, and the patient and caregiver.  Standardisation across 
sites was ensured by one to one training, regular multi-site meetings and the availability of a website 
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with instructional materials. There was no standardised pharmacy pre-hospital discharge 
intervention/medicine reconciliation provided across the sites involved.   
The type of Medication related problem was categorised using a modified version of the Hepler and 
Strand framework (8). Categories of problems, alongside an example of each are provided in S1. The 
significance of these problems was classified using Blix’s scale (9). A problem which had a significance 
rating of one was deemed low risk, two- moderate, three- major and a problem which was attributed 
a score of four was deemed potentially catastrophic. For a detailed breakdown of the Blix scoring 
system, see S1.   Scores of 2 were deemed clinically significant.  Associated clinical factors and the 
pharmacy recommendation were collated and the significance of the problem independently scored 
by two clinicians. Drugs involved were categorised according to their British National Formulary (BNF) 
classification (10).    
McNemar’s test was used to compare the difference between patients who were prescribed analgesia 
before admission and during InS:PIRE visit. Pearson’s chi-squared test was used to compare post-ICU 
opioid prescribing. Logistic regression determined if demographic factors were associated with 
clinically significant medication related problems. An unadjusted model was generated; variables with 
p-values less than 0.1 or clinically significant (age, severity of illness and length of exposure), were 
used to create the adjusted model.  IBM SPSS Statistics 241 was utilised (11).   
Results 
253 patients attended InS:PIRE across 5 sites. 183 patients had a documented pharmacy review and 
provided consented. Baseline demographics are shown in Table 1.   
The median number of medications prescribed before ICU admission was 5 (IQR 3-9), at ICU discharge 
6·5 (IQR 4-9); hospital discharge 7 (IQR 5-10); and at InS:PIRE 6 (IQR 4-9). Patients were prescribed a 
total of 1216 medications at InS:PIRE; 171 were associated with a medication related problem and 27 
necessary medications had been omitted, a total of 198 problems. 
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62·8% (n=115) patients required at least one pharmacy intervention, such as clarifying duration of 
treatment (n=44), followed by education (n=33), and correcting drug omissions (n=27).  27 pharmacy 
interventions were classified as minor, 141 as moderate, and 30 as severe. Thus, 86·4% (n=171) were 
clinically significant. A breakdown, alongside examples of the severe interventions are shown in Table 
2.   
Neurological drugs were most commonly problematic (n=65), including analgesic (n=45, e.g. Tramadol, 
Dihydrocodeine) and psychiatric medications (n=20, e.g., Sertraline)—a majority of these were in new 
medications prescribed at or after ICU 55·4% (n=36). Cardiovascular (n=40), gastrointestinal (n=34), 
and nutritional medications (n=25) were other common problematic classes.  
33·3% of patients (n=61) were prescribed regular analgesia before ICU; this increased to 60·7% (n=111) 
at InS:PIRE, an absolute increase of 27·4% (95% CI: 20·2% - 34·4%, p<0·001). Similarly, 22·4% (n=41) of 
patients were prescribed a regular opioid pre-ICU compared to 38·7% (n=71) at InS:PIRE, an absolute 
increase of 16·3% (95% CI: 9·8% -22·8%, p<0·001). There was not a significant difference between the 
use of opiates between surgical and medical admissions (p=0.445).  
Logistic regression was used to explore if clinical demographics predicted a clinically significant 
medication related problem. The adjusted model included age, ICU LOS, hospital LOS, APACHE II, 
number of days of RRT, number of days of ventilation, the number ICU discharge medications and the 
WHO analgesia classification at InS:PIRE  (Table 3)  The unadjusted analysis can be found in S2. 
Discussion 
This multi-centre study has demonstrated that over 60% of ICU patients have issues with medicines in 
the post hospital discharge period, with a large proportion of these issues related to psychiatric and 
pain medications. Longer durations of ICU treatment and complex ICU discharge prescriptions were 
identified as risk factor for a medication related problem.  
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These results are contextualized by evidence that providing a pharmacy review at transitions of care 
can improve safety and reduce 30-day hospital readmission in heart failure patients and primary care 
(12-13). Similarly, a recent study has shown that a pharmacy review, as part of a ‘bundled’ approach 
to care may reduce long term mortality in the sepsis group (14). More research is required to 
understand the potential of this intervention and how to integrate it within the complexities of ICU 
care.  We would recommend, based on our learning, that a medicines reconciliation exercise should 
be utilised at all transitions of care for this group of patients, especially at hospital discharge.  A clear 
plan for escalation and de-escalation of medicines should also be made, which should be shared with 
patients and ongoing care providers across the recovery arc.   
Our findings contrast with a recent Canadian study which demonstrated that opiate use did not 
increase after critical illness (16).  This may be explained by differences in how data was collected 
between these studies (in person vs retrospective electronic health records) and the timepoints at 
which opioid use was measured.  Other work has focussed on medication issues following critical 
illness and has shown a high rate of unintentional continuation of antipsychotics (17).   However 
inappropriate drug continuation did not appear to be the primary problem in our cohort, with only 
15% of neurological medication problems related to duration of treatment.  This is one of the first 
studies to explore all issues related to medication in the post discharge period and thus may be why 
a greater range of issues were found.  
The rise in opiate prescription is troublesome given concerns that the international opioid addiction 
epidemic, is in part fuelled by iatrogenic provision and easy access to opiates (17-18).  This post-
discharge excess may mirror the in-ICU challenge clinicians face: caught between a desire to relieve 
symptoms, and available tools that may worsen longer-term outcomes (19-20).    
Strengths of this study include its multi-centre involvement and its systematic approach to analysis, 
however there are limitations.  However, we did not control other services which patients attended;  
patients may have already had pharmacy reviews—that is, we have documented problems found after 
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usual care.  As such, we may have under-measured problems among participating patients, but 
generalizing from these patients to other populations should be done with caution. Additionally, a 
small number of patient self-referred to the programme; this may have impacted the results reported.  
In summary, this study demonstrated that over 60% of ICU patients have problems with medicines in 
the post hospital discharge period, with a large proportion of these problems related to psychiatric 
and pain medications.  
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Characteristic  Cohort (n=183) 
Gender, male (%) 97 (56·3) 
Age, years (median, IQR)* 58(50-65) 
ICU LOS, days (median, IQR) 12 (7-19) 
Hospital LOS, days (median, IQR) 28 (16-47) 
APACHE II (median, IQR) 20 (15-25) 
SIMD decile (median, IQR)** 3 (1-6) 
Number of patients ventilated (%) 159 (86·9) 
Median Duration, days (IQR) 8 (4-14) 
Number of patients requiring RRT (%) 35 (19·1) 
Median Duration, days (IQR) 7 (2-12) 
Number of patients requiring multiple vasoactive drugs (%) 90 (49·2) 
Median Duration, days (IQR) 3 (1-7) 
Medical diagnosis (%) 112 (61·2) 
Surgical diagnosis (%) 71 (38·8) 
Table 1: Baseline demographics of InS:PIRE participants 
*IQR: Interquartile Range 
**SIMD: The Scottish Index of Multiple Deprivation is a measure of socio-economic deprivation; decile 










Severe Medication Interventions 
(n=30) 
Clinical Example 
Drug Omissions (n=11) Prophylactic antibiotics not restarted in a splenectomy 
patient 
Adverse Event (n=2) Intolerable side effects from Pregabalin commenced 
during admission resulting in non-adherence and poor 
pain management 
New Treatment Recommendation 
(n=1) 
Omeprazole initiated for Aspirin related melaena 
Dose Increase (n=3) Titrate Gabapentin to pre-hospital admission dose to 
treat ongoing neuropathic pain  
Dose Decrease (n=2) Theophylline dose increased during admission, 
symptoms of toxicity at clinic, level checked, and dose 
decreased  
Clarification of treatment duration 
(n=5) 
Morphine commenced during admission, plan made 
with patient to reduce and stop 
Education (n=5) Non-adherence with Apixiban, patient was unaware of 
why it had been started. 
Monitoring/Referral (n=2) Patient on 5 analgesics with poorly controlled pain, 
referred to the chronic pain team  
 




Adjusted Logistic Regression 
 OR 95%CI p 
Age 0·99 0·96-1·02 0·55 
ICU LOS 0·95 0·89-1·02 0·14 
Hospital LOS 1·03 1·01-1·05 0·02 
APACHE II 1·04 0·99-1·10 0·16 
Days of Renal 
Replacement Therapy 
1·03 0·94-1·14 0·51 
Days of Ventilation 1·04 0·97-1·11 0·29 
Number of ICU 
Discharge Medications 
1·15 1·04-1·28 0·01 
WHO Classification at 
InS:PIRE 
- - - 
-No Analgesia 1 - - 
-Step 1* 2·02 0·84-4·86 0·12 
-Step 2* 5·20 2·07-13.20 0·001 
-Step 3* 1·95 0·61-6·26 0·26 
Table 3: Results of Multivariable Logistic Regression 
*Step 1 is non-opioid analgesia for mild pain (e.g. paracetamol), Step 2 is weak opioid analgesia for 
mild to moderate pain (e.g. codeine), and Step 3 is strong opioid analgesia for moderate to severe pain 
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